Free press releases distribution network?

Agency / Source: B3C Communications

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



BioGenes Announces Fast Development of Highly Specific Anti-idiotypic Antibodies - BioGenes GmbH, offers the development of highly specific anti-idiotypic antibodies. Anti-idiotype antibodies are antibodies against the antigen binding site of another antibody - Biogenes.de
BioGenes Announces Fast Development of Highly Specific Anti-idiotypic Antibodies

 

PRZOOM - /newswire/ - Traunstein, Germany, 2011/03/07 - BioGenes GmbH, offers the development of highly specific anti-idiotypic antibodies. Anti-idiotype antibodies are antibodies against the antigen binding site of another antibody - Biogenes.de.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BioGenes, a specialist for complex and customized antibody projects, offers the development of highly specific anti-idiotypic antibodies. Anti-idiotype antibodies are antibodies against the antigen binding site of another antibody.

The antigen binding site of the anti-idiotype antibody is similar in structure to the original antigen. Therefore, anti-idiotypic monoclonal antibodies can be used to mimic the structure of the original antigen. They can serve as surrogate for tumor-associated antigens in vaccination strategies by triggering humoral and cellular immune responses against the tumor antigen.

BioGenes’ scientists are specialized in complex projects and have developed premium quality anti-idiotypic antibodies even with small antibody amounts in less than four months.Antibodies developed by BioGenes are a valuable basis for therapeutic antibody development and an appropriate tool for validating targets in proteomics research.

About BioGenes

BioGenes GmbH (biogenes.de) specialises in highly sophisticated antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, which include eight of the ten largest pharmaceutical companies in the world.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: B3C Communications

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BioGenes Announces Fast Development of Highly Specific Anti-idiotypic Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sabine Duntze - B3C.de 
+49 8619098220 info[.]biogenes.de
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any B3C Communications securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From B3C Communications / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  MagLar, Inc.

Visit  Persistence Market Research (P) Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today